|
Dr. Patrick Colin joined Axcan Pharma in 1994 as director of clinical research and was subsequently appointed vice president of clinical research in 2000, and vice president of research and development in 2003. He is currently responsible for all aspects of drug development, including pre-clinical toxicology, pharmaceutical development, and Phase I to III clinical research. He began his career at Bristol Myers Squibb in 1987 where he worked in various clinical research positions.
Dr. Colin is extensively published in several areas of drug development and is a guest professor at both the University of Montreal and Laval University in Quebec City. He holds a Doctorate of Philosophy (Ph.D.) degree in pharmaceutical sciences from the University of Montreal (1987) and a bachelor�s degree in pharmacy from the University of Montreal (1980). He is an active member of the Quebec Order of Pharmacists and various other scientific organizations. | 